We are live on ! Find out more
TVRD icon

Tvardi Therapeutics

81 hedge funds and large institutions have $96.9M invested in Tvardi Therapeutics in 2016 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

543% more call options, than puts

Call options by funds: $1.41M | Put options by funds: $220K

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

16% more funds holding

Funds holding: 70 → 81 (+11)

6% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 18

4.85% less ownership

Funds ownership: 47.41% → 42.55% (-4.9%)

15% less capital inflows, than outflows

Capital inflows: $10M | Capital outflows: $11.8M

Holders
81
Holders Change
+11
Holders Change %
+15.71%
% of All Funds
2.15%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
21
Increased
19
Reduced
18
Closed
9
Calls
$1.41​M
Puts
$220​K
Net Calls
+$1.19​M
Net Calls Change
+$1.24​M

TVRD Hedge Fund Activity: Q3 2016 in Review

81 of the 3,760 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2016, worth a combined $96.9M — up 53% from $63.5M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new TVRD positions and 9 closed out — a net gain of 12 holders — while 19 added to existing stakes and 18 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.49M. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $5.01M sold.

  • 81 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2016, up from 70 in Q2 2016.
  • Funds reported $96.9M of Tvardi Therapeutics stock for Q3 2016, up 53% quarter-over-quarter.
  • 21 funds opened new Tvardi Therapeutics positions in Q3 2016 and 9 closed out, a net change of +12 holders.
  • The largest Tvardi Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $1.49M added.
  • The largest Tvardi Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $5.01M sold.

Based on aggregated 13F filings for Q3 2016.